<DOC>
	<DOCNO>NCT01227837</DOCNO>
	<brief_summary>In double blind study patient resynchronization pacemaker- AICD assign Omega3 placebo randomly , result indicate Omega3 effect placebo mortality , BNP level 6 minute walk test .</brief_summary>
	<brief_title>Effect omega3 Congestive Heart Failure</brief_title>
	<detailed_description>Introduction : Widely use lipid lower agent , Omega 3 fatty acid demonstrate possess potential reduce risk cardiovascular event patient suffer chronic heart condition . In double -blinded randomize placebo-controlled clinical trial , aim investigate possible beneficial effect Omega-3 supplement echocardiographic parameter brain natriuretic peptide ( BNP ) plasma level patient suffer congestive heart failure ( CHF ) . Methods Materials : 100 patient class II III CHF , tri-chamber pacemaker automate defibrillator ( CRT-AICD ) initially recruit among 70 subject consent participate . Subjects randomly assign match two treatment group . 42 patient allocate two gram/day dose omega-3 capsule 28 subject allocate placebo group . Demographic feature BNP plasma level , 6-minute walk test echocardiographic parameter patient record baseline 6 month implementation treatment protocol . Data gather analyzed evaluate beneficial effect omega-3 supplement compare placebo . Conclusion : Beneficial effect Omega-3 supplementation CHF patient dramatic initially presume</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>EF &lt; 40 % sinus rhythm accept randomization trichamber pacemaker Exclusion criterion : survival le 6 month class IV heart failure use drug study protocol</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>omega 3</keyword>
	<keyword>CRT_AICD</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>CHF</keyword>
</DOC>